conference paper · IOP Conference Series Materials Science and Engineering
Managing haemostatic disorders is vital to prevent serious complications caused by thrombosis across atherosclerotic arteries supplying the heart, brain, and limbs, as well as stagnant blood in heart chambers and veins. Current chemically synthesised anticoagulants present significant clinical challenges, including possible long-term adverse effects, a lack of specific antidotes for most medications, and difficulties in balancing cost against therapeutic efficacy. Biogenic or green-synthesised silver nanoparticles provide a potential alternative to resolve many of these limitations. Synthesised using biological methods, these novel nanomaterials exhibit notable anticoagulant and thrombolytic properties. Research focuses on their synthesis, characterisation methods, and prospective medical utility as therapeutic agents within the expanding field of nanomedicine, offering new strategies for safer and more effective blood clot management.
Blood clots can trigger life-threatening conditions such as strokes and heart attacks. Traditional anticoagulant medications are often expensive, risk adverse side effects, and typically lack reversing antidotes. Exploring biogenic silver nanoparticles produced through green synthesis could lead to safer, more accessible, and more effective treatments for managing haemostatic disorders and dissolving dangerous clots.
This research points towards potential pharmaceutical applications in developing alternative anticoagulant and clot-dissolving therapies for healthcare providers. However, based strictly on the abstract, the work is a review of novel biogenic nanoparticles, placing the technology at an early conceptual research stage. Significant experimental characterisation, safety profiling, and clinical testing would be required before these nanomaterials could be considered for commercial medical formulations.
AI-generated from the published abstract. Always read the original work before citing.
Abstract Effective management of haemostatic disorders in patients is pertinent in order to prevent complications attributable to incidences of thrombosis in atherosclerotic arteries to the heart, brain, limbs, stagnant blood in veins and heart chambers. The use of existing chemical agents are not without a number of challenges, varying from potential for unknown long-term adverse effect through lack of antidote for most agents, balance between cost and efficacy among others. However, advent of biogenic silver nanoparticles with anticoagulant and thrombolytic potentials has opened up a window of opportunity to address most of the shortcomings of the chemical synthesized anticoagulants. This review examined green synthesized novel silver nanoparticles, their characterization and possible application as anticoagulant and thrombolytic agents in the evolving area of nanomedicine.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1088/1757-899x/805/1/012043
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
